tm logo
DUCYMBRO
REGISTERED

on 05 Jan 2024

Last Applicant/ Owned by

MERCK SHARP & DOHME LLC

126 East Lincoln Ave.P.O. Box 2000Rahway, NJ 07065

US

Serial Number

2039651 filed on 14th Jul 2020

Registration Number

TMA1216788 registered on 05th Jan 2024

Registration expiry Date

05th Jan 2034

Correspondent Address

Bay Adelaide Centre, East Tower22 Adelaide St. WestTORONTO

ONTARIO

CA

M5H4E3

DUCYMBRO

Trademark usage description

pharmaceutical preparations and substances for the prevention and treatment of bone, cardiovascular, hematological, hepatological, immunological, gast Read More

Classification Information


Class [005]
Pharmaceutical preparations and substances for the prevention and treatment of bone, cardiovascular, hematological, hepatological, immunological, gastrointestinal, musculoskeletal, nephrological, oncological, ophthalmic, pulmonary, renal, respiratory, and urological diseases and disorders; Pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; Pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders, namely bacterial skin infections, fungal skin infections, viral skin infections, parasitic skin infections, psoriasis, eczema, and dermatitis; Pharmaceutical preparations and substances for the prevention and treatment of diseases and disorders of the endocrine system, namely, glucagonoma, growth and thyroid disorders, diabetes, metabolic syndrome, obesity, weight loss and weight management; Pharmaceutical preparations and substances for the prevention and treatment of genitourinary diseases and disorders, namely, infertility, sexually transmitted diseases, inflammatory pelvic diseases; Pharmaceutical preparations and substances for the prevention and treatment of gynecological diseases and disorders, namely amenorrhoea, dysmenorrheal and diseases and disorders relating to sexual reproduction and fertility; Pharmaceutical preparations and substances for the prevention and treatment of metabolic diseases and disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, arthritis, obesity and hypothyroidism; Pharmaceutical preparations and substances for the prevention and treatment of neurological diseases and disorders, namely, schizophrenia pain, neuropathic pain; Pharmaceutical preparations and substances for the prevention and treatment of psychiatric diseases and disorders, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia, psychoses and bipolar disorders; Pharmaceutical preparations and substances for the prevention and treatment of Respiratory Syncytial Virus (RSV); Pharmaceutical preparations substances for the prevention and treatment of autoimmune diseases, asthma, cancer and tumors, chronic cough, diabetes, hypertension, insomnia, intestinal infections, skin disorders, namely, dermatitis, skin pigmentation diseases, psoriasis, acne, rosacea, ichthyosis, urticaria and urinary incontinence; Pharmaceutical preparations, namely, anti-bacterials, antibiotics, anti-fungals, anti-infectives, anti-inflammatories, anti-parasitics, and antivirals; Human vaccine preparations; Inhaled pharmaceutical preparations for the prevention and treatment of cardiovascular diseases and disorders


Classification kind code

11

Mark Details


Serial Number

2039651

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 26
on 21st Sep 2023
Approved
Submitted for opposition 27
on 21st Sep 2023
Approval Notice Sent
Submitted for opposition 48
on 07th Sep 2023
Agent Changed
Submitted for opposition 22
on 11th May 2023
Search Recorded
Submitted for opposition 20
on 11th May 2023
Examiner's First Report
Submitted for opposition 135
on 10th Aug 2022
Amendment to Application
Submitted for opposition 287
on 04th Aug 2022
Pre-Assessment Letter Sent
Submitted for opposition 30
on 14th Jul 2020
Filed
Submitted for opposition 1
on 14th Jul 2020
Created
Submitted for opposition 31
on 14th Jul 2020
Formalized